{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:25:19Z","timestamp":1791033919856,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1213\/ane.0b013e318202cc8d","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T04:07:22Z","timestamp":1291349242000},"page":"448-453","source":"Crossref","is-referenced-by-count":102,"title":["Combined Catechol-O-Methyltransferase and \u03bc-Opioid Receptor Gene Polymorphisms Affect Morphine Postoperative Analgesia and Central Side Effects"],"prefix":"10.1213","volume":"112","author":[{"given":"Yuri","family":"Kolesnikov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gabovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Voiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Veske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-26-20210902","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0885-3924(00)00228-1","article-title":"Opioid poorly-responsive cancer pain. Part 1. Clinical considerations.","volume":"21","author":"Mercadante","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"R2-26-20210902","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0885-3924(00)00236-0","article-title":"Opioid poorly-responsive cancer pain. Part 2. Basic mechanisms that could shift dose response for analgesia.","volume":"21","author":"Mercadante","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"R3-26-20210902","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jpainsymman.2005.01.011","article-title":"Molecular biology of opioid analgesia.","volume":"29","author":"Pasternak","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"R4-26-20210902","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.","volume":"95","author":"Bond","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"R5-26-20210902","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1471-4159.2004.02340.x","article-title":"Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor.","volume":"89","author":"Beyer","year":"2004","journal-title":"J Neurochem"},{"key":"R6-26-20210902","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1213\/01.ane.0000231634.20341.88","article-title":"A genetic association study of the functional A118G polymorphism of the human opioid receptor gene in patients with acute and chronic pain.","volume":"103","author":"Janicki","year":"2006","journal-title":"Anesth Analg"},{"key":"R7-26-20210902","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00000542-200608000-00016","article-title":"Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy.","volume":"105","author":"Chou","year":"2006","journal-title":"Anesthesiology"},{"key":"R8-26-20210902","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/ALN.0b013e318182af21","article-title":"A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia.","volume":"109","author":"Sia","year":"2008","journal-title":"Anesthesiology"},{"key":"R9-26-20210902","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenetics"},{"key":"R10-26-20210902","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1126\/science.1078546","article-title":"COMTval158met genotype affects mu opioid neurotransmitter responses to a pain stressor.","volume":"299","author":"Zubieta","year":"2003","journal-title":"Science"},{"key":"R11-26-20210902","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pain.2005.03.032","article-title":"The val158met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients.","volume":"116","author":"Rakvag","year":"2005","journal-title":"Pain"},{"key":"R12-26-20210902","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pain.2006.10.023","article-title":"Exploring joint effects of gene and the clinical efficacy of morphine for cancer pain.","volume":"130","author":"Reyes-Gibby","year":"2007","journal-title":"Pain"},{"key":"R13-26-20210902","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5","article-title":"Validation Edmonton Symptom Assessment Scale.","volume":"88","author":"Chang","year":"2000","journal-title":"Cancer"},{"key":"R15-26-20210902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/ps040423","article-title":"Bioinformatic analysis of the human opioid receptor (OPRM1) splice and polymorphic variants.","volume":"4","author":"Xin","year":"2002","journal-title":"AAPS PharmSci"},{"key":"R16-26-20210902","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00000542-200503000-00028","article-title":"Pharmacogenetics of anesthetic and analgesic agents.","volume":"102","author":"Palmer","year":"2005","journal-title":"Anesthesiology"},{"key":"R17-26-20210902","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1517\/14656566.8.14.2235","article-title":"The pharmacogenetics of analgesia.","volume":"8","author":"Stamer","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R18-26-20210902","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.mp.4000556","article-title":"Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.","volume":"4","author":"Gelernter","year":"1999","journal-title":"Mol Psychiatry"},{"key":"R19-26-20210902","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.tpj.6500327","article-title":"Clinical response to morphine in cancer patients and genetic variation in candidate genes.","volume":"5","author":"Ross","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R20-26-20210902","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0304-3959(95)00128-X","article-title":"Age is the best predictor of postoperative morphine requirements.","volume":"64","author":"Macintyre","year":"1996","journal-title":"Pain"},{"key":"R21-26-20210902","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1176\/ajp.156.6.842","article-title":"Gender and age influences on human brain mu-opioid receptor binding measured by PET.","volume":"156","author":"Zubieta","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R22-26-20210902","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0091-3057(82)90444-0","article-title":"Neuroleptic and analgesic interactions upon pain and activity measures.","volume":"16","author":"Bodnar","year":"1982","journal-title":"Pharmacol Biochem Behav"},{"key":"R23-26-20210902","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00572268","article-title":"Modification of the antinociceptive activity of morphine by centrally administered ouabain and dopamine.","volume":"21","author":"Calcutt","year":"1971","journal-title":"Psychopharmacologia"},{"key":"R24-26-20210902","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1523\/JNEUROSCI.21-19-07788.2001","article-title":"Potentiation of opioid analgesia in dopamine2 receptor knock-out mice: evidence for a tonically active anti-opioid system.","volume":"21","author":"King","year":"2001","journal-title":"J Neurosci"},{"key":"R25-26-20210902","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pain.2006.09.022","article-title":"Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both 2 and 3 adrenergic receptors.","volume":"128","author":"Nackley-Neely","year":"2007","journal-title":"Pain"},{"key":"R26-26-20210902","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00008571-200201000-00002","article-title":"The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucoronide but not that of morphine.","volume":"12","author":"Lotsch","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R27-26-20210902","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00003088-200443140-00003","article-title":"Genetic predictors of the clinical response to opioid analgesics.","volume":"43","author":"Lotsch","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R28-26-20210902","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0165-6147(00)01616-3","article-title":"Incomplete cross tolerance and multiple mu opioid peptide receptors.","volume":"22","author":"Pasternak","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"R29-26-20210902","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1: recent advances and clinical relevance.","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R30-26-20210902","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/cncr.23292","article-title":"Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.","volume":"112","author":"Ross","year":"2007","journal-title":"Cancer"},{"key":"R31-26-20210902","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.clpt.6100095","article-title":"Pharmacogenetics of opioids.","volume":"87","author":"Somogyi","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0b013e318202cc8d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:18:51Z","timestamp":1786112331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201102000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0b013e318202cc8d","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.8655956.9171056","asserted-by":"object"}]},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}